

Sub
C1
cont
21/8
antibody.

27. A hybridoma cell line which produces the antibody of claim 21 or 24. 14

Br 159
28. A dimeric molecule comprising the antibody of claim 24 linked to a heterologous immunoglobulin. 14 A

Sub
C2
29. A homodimeric molecule comprising any two antibodies of claims 8, 10, 19, 21, 22 or 24. --

REMARKS

Claims 1-10, 12, 13, and 15-18 are pending in the application and are the subject of the office action issued by the Examiner. In the above amendment, claim 8 has been amended, and it is believed that this amendment puts claim 8 in condition for allowance, per the Examiner's comments in the Office Action. Claims 1-7, 12, 13, and 15-18 were canceled without prejudice. Claims 19-29 have been added. Claims 19-29 have been added by Applicants so that the claims in the instant application more closely correspond to those claims in Applicants' co-pending application relating to Apo-2 polypeptides which Examiner Kaufman is also presently examining. Added claims 19-29 are fully supported by the specification and do not introduce new matter.

The specification has also been amended to correct various inadvertent typographical errors in some reference citations, and to reflect the current address for the ATCC depository.

Information Disclosure Statement

Applicants thank the Examiner for forwarding the initialed 1449 Forms with the Office Action and informing Applicants that some references cited on the 1449 Form filed in August, 1998 could not be located. Replacement copies of the references identified as reference nos. 91, 102, 105, 114, 115, 119, 161, 166, 173, 191, 201 and 265 are enclosed herewith, along with a courtesy copy of that Form 1449 filed in August, 1998. The Examiner's consideration of these references is respectfully requested.

Applicants are also filing concurrently with this Amendment, a Supplemental Information Disclosure Statement which identifies seven (7) foreign published patent applications. As the Examiner will note, several of these published patent application references have US priority filing dates prior to Applicants' US priority filing date, and several of these references have US priority filing dates subsequent to Applicants' US priority filing date. A copy of Applicants' own published PCT application relating to Apo-2 polypeptide is included with this Supplemental Information Disclosure Statement. It is believed that one or more of these references (as well as the WO98/35986 and WO98/41629 references previously cited by Applicants) may present interference issues. The undersigned attorney of record would appreciate an opportunity to discuss these issues with the Examiner at the Examiner's convenience.

Drawings

The required changes needed for the numbering of the figures are acknowledged. Upon indication of the notice of allowance for the instant application, Applicants will file formal drawings with the appropriate numbering for the figures and file any amendments to the specification needed to bring the application into conformance with the formal drawings.

Section 112 Rejections

In view of the cancellation of Claims 1-7, 12, 13, and 15-18 in the above amendment, it is believed that the various Section 112 rejections are now moot. Applicants wish to emphasize that the cancellation of the subject claims is without acquiescence to the Section 112 rejections in the present Office Action. Applicants wish to make the present claims directed to Apo-2 antibodies more closely correspond to their respective claims directed to Apo-2 polypeptides.

Before examination of the claims in this application proceeds further, the undersigned would like an opportunity to discuss with the

Examiner the implications of the art references noted above on the claims directed to anti-Apo-2 antibodies.

Respectfully submitted,
GENENTECH, INC.

Date: February 24, 2000

By: Diane L. Marschang
Diane L. Marschang
Reg. No. 35,600

1 DNA Way
So. San Francisco, CA 94080-4990
Phone: (650) 225-5416
Fax: (650) 952-9881

B